Evidence map›Paper›PMID 34422068›Full record

ArticleEvidence-based complementary and alternative medicine : eCAM2021

Identification of Potential Bioactive Ingredients and Mechanisms of the Guanxin Suhe Pill on Angina Pectoris by Integrating Network Pharmacology and Molecular Docking.

Mingmin Wang, Shuangjie Yang, Mingyan Shao, Qian Zhang, Xiaoping Wang, Linghui Lu, Sheng Gao, Yong Wang, Wei Wang

Open access · hybridAbstract read
In one paragraph

Article in Evidence-based complementary and alternative medicine : eCAM, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Current drug discovery technologies · 2025
    Article
  3. Article
  4. Inhibitory Effects ofEvidence-based complementary and alternative medicine : eCAM · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Mingmin WangDongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100700, China.ORCID https://orcid.org/0000-0003-2615-5572
Shuangjie YangSchool of Chinese Medicine, Beijing University of Chinese Medicine, Beijing 100029, China.
Mingyan ShaoSchool of Life Sciences, Beijing University of Chinese Medicine, Beijing 100029, China.
Qian ZhangSchool of Chinese Medicine, Beijing University of Chinese Medicine, Beijing 100029, China.
Xiaoping WangSchool of Chinese Medicine, Beijing University of Chinese Medicine, Beijing 100029, China.
Linghui LuSchool of Chinese Medicine, Beijing University of Chinese Medicine, Beijing 100029, China.
Sheng GaoDepartment of Gastroenterology, The Shanghai Tenth People's Hospital, Tongji University, Shanghai 200092, China.
Yong WangSchool of Chinese Medicine, Beijing University of Chinese Medicine, Beijing 100029, China.ORCID https://orcid.org/0000-0003-3652-8037
Wei WangDongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100700, China.ORCID https://orcid.org/0000-0002-3172-0313
Beijing University of Chinese Medicine · CNDongzhimen Hospital Affiliated to Beijing University of Chinese Medicine · CNTongji University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Guanxin Suhe pill (GSP), a traditional Chinese medicine, has been widely used to treat angina pectoris (AP) in Chinese clinical practice. However, research on the bioactive ingredients and underlying mechanisms of GSP in AP remains scarce. In this study, a system pharmacology approach integrating gastrointestinal absorption (GA) evaluation, drug-likeness (DL) evaluation, target exploration, protein-protein-interaction analysis, Gene Ontology (GO) enrichment analysis, network construction, and molecular docking was adopted to explore its potential mechanisms. A total of 481 ingredients from five herbs were collected, and 242 were qualified based on GA and DL evaluation. Target exploration identified 107 shared targets between GSP and AP. Protein-protein interaction identified VEGFA (vascular endothelial growth factor A), TNF (tumor necrosis factor), CCL2 (C-C motif chemokine ligand 2), FN1 (fibronectin 1), MMP9 (matrix metallopeptidase 9), PTGS2 (prostaglandin-endoperoxide synthase 2), IL10 (interleukin 10), CXCL8 (C-X-C motif chemokine ligand 8), IL6 (interleukin 6), and INS (insulin) as hub targets for GSP, which were involved in the inflammatory process, ECM proteolysis, glucose metabolism, and lipid metabolism. GO enrichment identified top pathways in the biological processes, molecular functions, and cell components, explaining GSP's potential AP treatment mechanism. Positive regulation of the nitric oxide biosynthetic process and the response to hypoxia ranked highest of the biological processes; core targets that GSP can regulate in these two pathways were PTGS2 and NOS2, respectively. Molecular docking verified the interactions between the core genes in the pathway and the active ingredients. The study lays a foundation for further experimental research and clinical application.

Identifiers

PMID34422068
PMCPMC8373492
OpenAlexW3192356136

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.